28 May 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that the updated results of Phase Ib study of CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor (“TGCT”), will be presented at the 2023 American Society of Clinical Oncology (“ASCO”) annual meeting held in Chicago, USA from June 2 to June 6, 2023.

27 April, 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”hereafter) today announced first patient dosing of “A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor” in Beijing Jishuitan Hospital.

Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting.

3 April 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced that its next-generation FGFR4 mutant inhibitor ABSK012 has been granted the orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of Soft Tissue Sarcoma (STS).

16 March 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as “Abbisko Therapeutics” hereafter) announced that the U.S. FDA had approved its CSF-1R inhibitor pimicotinib（ABSK021）for a randomized, double-blind, placebo-controlled, multicenter Phase III clinical study in patients with giant cell tumor of the tendon sheath.